This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Oxybutynin vaginal ring
Teva Pharmaceutical Industries Ltd.
Drug Names(s): DR-3001
Description: Oxybutynin vaginal ring (DR-3001) is a silicone-based, flexible ring designed to be dosed once a month. This delivery system for the intravaginal delivery of oxybutynin has been developed to minimize the presystemic first-pass metabolism that occurs with orally administered oxybutynin.
Deal Structure: Oxybutynin vaginal ring was originally developed by Enhance Pharmaceuticals and Schering AG.
In 2002, Barr Pharmaceuticals acquired Enhance Pharmaceuticals.
In April 2004, Schering AG Group announced that it has signed an agreement with Barr Laboratories. Under this agreement, Schering transfers its worldwide marketing and sales rights to the oxybutynin transvaginal ring. Barr assumes all remaining development efforts and will pay Schering a milestone payment upon final FDA approval as well as an ongoing royalty based on product sales upon commercialization of the product.
In December 2006, Bayer acquired Schering AG.
In July 2008, Teva Pharmaceutical and Barr Pharmaceuticals announced that they have signed a definitive agreement under which Teva will acquire Barr. The acquisition was completed in December 2008.
Partners: Bayer AG
Oxybutynin vaginal ring News
Pink Sheet Weekly Trademark Review September 10, 2013
Additional information available to subscribers only: